中国核电：公司未来将继续进行新型堆照同位素的开发，继续建设开发第二套同位素在线辐照生产装置

Core Viewpoint - The company is actively developing its strategic emerging industries, previously referred to as the agile end business, and has made significant advancements in various projects [1] Group 1: Business Development - The company has rebranded its agile end business to strategic emerging industries and is systematically promoting its related industrial layout [1] - The company has established a wholly-owned subsidiary, China Nuclear Power Technology (Shanghai) Co., Ltd., focusing on the research and manufacturing of perovskite photovoltaic components [1] - The company has built the first fully automated production line in the industry for rigid 1600×1200mm² components, which is the first domestically produced line in the country and has leading technical indicators in the industry [1] Group 2: Isotope Production - The company has established a medical isotope production base at Qinshan Nuclear Power, achieving commercial production of isotopes such as Carbon-14, Yttrium-90, Lutetium-177, and Strontium-90 [1] - This initiative has broken the dependency on imported sources, contributing significantly to the health sector in China [1] - The company plans to continue the development of new type pile irradiation isotopes and is working on the construction of a second online irradiation production facility for isotopes [1]